Background: Exenatide, a glucagon-like peptide-1 receptor agonist administered by self-injection, decreases plasma glucose, glycosylated hemoglobin (HbA 1c ), and weight in patients with type 2 diabetes. ITCA 650 is an investigational new drug that provides continuous subcutaneous delivery of exenatide.
INTRODUCTION
In the United States, type 2 diabetes affects ϳ25.8 million people. 1 Treatment often requires daily blood glu-cose monitoring and multiple therapeutic interventions, including diet, oral hypoglycemic medications, and/or insulin or 1 of its analogues and/or injectable incretin mimetic agents. 2 However, depending on the stage of the disease and the treatment used, glycosylated hemoglobin (HbA 1c ) target levels Յ7.0% are achieved in approximately one half of patients administered antihyperglycemic drugs. [3] [4] [5] [6] Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of therapeutic agents for the treatment of type 2 diabetes that have multiple actions, including enhancement of insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and reduction of food intake and weight. 7, 8 Exenatide was the first approved GLP-1 receptor agonist and exhibits a t ½ of 2.4 hours, measurable plasma levels for ϳ10 hours, and clinical effects that persist for ϳ8 hours after a single subcutaneous (SC) injection. 9, 10 A once-weekly exenatide injection has recently been approved for use in type 2 diabetes. This formulation consists of microspheres containing exenatide and a poly (lactide-co-glycolide) polymeric matrix, which slowly releases exenatide through diffusion and erosion. 11 A once-weekly injection of exenatide has been shown to significantly reduce HbA 1c , fasting blood glucose, postprandial hyperglycemia, and weight. 12 Long-term studies extending to 48 weeks indicate that continued use of exenatide BID or an exenatide onceweekly injection for up to 4 years produces sustained reductions in HbA 1c and weight. 13, 14 The main limitations of exenatide BID are the need for BID injection and a high incidence of gastrointestinal adverse effects, especially nausea and vomiting, attributed to fluctuations in exenatide blood concentrations with high peak blood concentrations shortly after each administration. An additional limitation of depot formulations of GLP-1 receptor agonists is that once injected, the depot cannot be removed should the patient experience complications. Less nausea and vomiting is seen with the depot formulation of exenatide; however, 6 to 7 weeks are required to reach steadystate concentrations, and circulating therapeutic drug concentrations persist ϳ10 weeks after the drug is discontinued. The need for SC injection with all currently available GLP-1 receptor agonists, injection site reactions/discomfort, and the inconvenience of having to reconstitute and refrigerate the once-weekly formulation may create a barrier to initial use as well as longterm patient adherence and compliance with therapy.
ITCA 650 is a miniature osmotic pump system that delivers zero-order, continuous SC release of exenatide at a precise predetermined rate for up to 12 months with a single placement. 15, 16 The sterile product with dimensions similar to a small matchstick is inserted subcutaneously in the abdominal region with a placement tool by using an aseptic technique during a short office procedure; the procedure can be performed by a physician, physician's assistant, or other licensed practitioner. 15 Removal requires skin preparation and a small (ϳ5 mm) incision. The procedures to place, remove, and replace nonbiodegradable drug delivery systems is reimbursed in the United States by insurance companies and other payers.
Delivery of exenatide with this system is predicted to result in rapid attainment and maintenance of therapeutic drug concentrations, provide 100% adherence/ compliance with therapy, improve glycemic control, and produce a lower incidence of gastrointestinal effects due to more constant and predictable exenatide levels. 15 This Phase Ib, randomized, open-label, multicenter, 4-week study evaluated the tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of ITCA 650 in patients with type 2 diabetes.
PATIENTS AND METHODS
This randomized, open-label study consisted of a 3-week screening period, a 4-week treatment period, and a 1-week posttreatment safety follow-up period. The primary objective of the study was to evaluate the tolerability of ITCA 650 in patients with type 2 diabetes. The secondary objectives were to characterize the PK profile of ITCA 650 and its effects on the PD measures of glucose metabolism in patients with type 2 diabetes. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation guidelines for Good Clinical Practice and applicable regulatory requirements. An institutional review board reviewed and approved the protocol, consent form, and patient information before any patient was enrolled in the study. Written informed consent was obtained from each patient at the screening visit before performing any study procedures. months, a stable weight, and who were treated with diet and exercise alone or in combination with a stable dose of metformin monotherapy, thiazolidinedione monotherapy, or metformin plus thiazolidinedione combination therapy (Ն3 months before screening) were eligible to participate. Patients were required to have an HbA 1c level Ն6.5% and Յ10%, a fasting plasma glucose (FPG) level Ͻ270 mg/dL, and a fasting C-peptide level Ͼ0.8 ng/mL at screening. Patients who were being treated with diet and exercise alone had to have a FPG level Ն126 mg/dL at screening. Women of childbearing potential had to have a negative pregnancy test result at screening and agree to use an acceptable form of contraception during the study.
Patients were excluded if they previously had been treated with exenatide; had received sulfonylureas, dipeptidyl peptidase-IV inhibitors, acarbose, or insulin within 3 months of screening; or had been treated with an investigational agent within 30 days before screening. Patients with type 1 diabetes or a history of diabetic ketoacidosis were excluded, as were those with other medical conditions that could complicate participation in the trial.
Study Procedures
Patients were admitted for a 5-day inpatient stay and randomized on a 1:1 basis to receive either 10 or 20 g/d of ITCA 650 on study day 1. Once it was confirmed that the 10-and 20-g/d doses were well tolerated, an additional cohort of patients was recruited and randomized to receive either 40 or 80 g/d of ITCA 650. All patients were followed up for 4 weeks, and the device was removed on day 29. Patients were followed up for an additional 7 days after the device was removed for evaluation of safety. The randomization code and allocation were managed by a contract research organization (Medpace, Inc., Cincinnati, OhioMedpace, Inc., Cincinnati, Ohio).
Site personnel placed ITCA 650 study devices with a placement tool subcutaneously into 1 of the 4 abdominal quadrants by using an aseptic technique (see Description in Supplemental Table in the online version at http://dx.doi.org/10.1016/j.clinthera.2013.03.011). During removal, the ITCA 650 is immobilized, and a small (ϳ5 mm) incision is made directly over 1 end of the device, which is then gently pushed toward the incision and removed with a hemostat.
Study Assessments
Patients underwent a complete physical examination, including vital signs (heart rate, blood pressure, and temperature) at screening and on day 29 (or sooner, if early termination occurred), followed by a brief physical examination on days Ϫ1, 8, 15, 22, and 36. A 12-lead ECG was obtained at screening and days Ϫ1, 5, and 29 or at the time of early termination. A 3-hour breakfast meal tolerance test was obtained on days Ϫ1, 5, 15, and 29 or upon early termination.
Safety was assessed from adverse events, clinical laboratory test results, physical examination, vital signs (heart rate, blood pressure, and body temperature), and ECG findings. Adverse events were reported by patients or assessed by clinicians, and they were categorized as either mild (transient and not interfering with activities of daily living), moderate (causing a low level of inconvenience possibly interfering with activities of daily living and ameliorated by simple therapeutic measures), or severe (interrupting the usual daily activities and requiring systemic drug therapy or other treatment).
All fasting laboratory samples were collected after a Ն10-hour fast, and a central laboratory was used for all study-related tests. Laboratory evaluations were performed at screening, day Ϫ1, day 1, days 2 to 5, and days 8, 15, 22, and 29 or upon early termination. Patients used a home glucose monitor to measure FPG each morning before breakfast. Other PD variables were assessed at regular intervals, including weight, insulin, proinsulin, C-peptide, glucagon, HbA 1c , and fructosamine. Two-hour postprandial glucose, insulin, and glucagon plasma concentrations were measured. AUC values were determined for glucose, insulin, and glucagon. ␤-cell function was assessed by using the homeostasis model index (HOMA)-␤, and insulin resistance was assessed according to HOMA-insulin resistance. Total cholesterol, triglycerides, LDL-C, HDL-C, and nonesterified fatty acid levels also were determined. Insulin, proinsulin, C-peptide, and glucagon levels were determined by using an electrochemiluminescence immunoassay. Fructosamine, glucose, lipid and lipoprotein, and free fatty acid levels were determined by using photometry. HbA 1c levels were determined according to HPLC.
Blood was obtained for PK analysis at baseline and on day 1; days 2 to 5; days 8, 15, and 22; before and after removal of the ITCA 650 device on day 29 or upon early termination; and on days 30 and 36. Plasma Clinical Therapeutics was shipped on dry ice to Midwest Bioresearch, LLC (Skokie, Illinois) for the determination of plasma exenatide concentrations, which were measured by using a validated electrochemiluminescent method with a lower limit of quantitation of 29.3 pg/mL. C max and T max were determined over the entire study period. C min and T min were determined from 24 through 672 hours after placement. C SS was determined as the average of all concentrations measured between 24 hours and 672 hours after placement. AUC SS was determined as AUC SS ϭ C SS * 24 hours. Concentrations below the assay limit of quantitation were assigned a value equal to the lower limit of quantitation (29.3 pg/mL). Nominal time points for each sample were used in the PK analysis. PK and statistical calculations were performed by using Microsoft Excel 2000 version 9.0 and Microsoft Office Excel 2007 (Microsoft Corporation, Redmond, Washington).
Anti-exenatide antibodies were measured from blood samples obtained on day 1 before placement of ITCA 650, on day 29 (or upon early termination), and on day 36. Serum was obtained and shipped on dry ice to Midwest Bioresearch. Antibody screening was conducted at Midwest Bioresearch by using a validated ELISA procedure.
Statistical Analysis
One hundred fifty-one patients were screened to ensure that at least 40 and up to 48 patients were randomized between 4 treatment groups of 10 to 12 patients each. The analysis of data from this study was primarily exploratory in nature, and no formal hypothesis was tested. The safety population consisted of all patients randomized to treatment who received study medication. The evaluable population consisted of randomized patients who received complete pretreatment and posttreatment PD assessments. The PK population consisted of randomized patients who received study medication and provided at least 1 PK sample.
An ANCOVA model with treatment as a factor and baseline value as a covariate was used to test the treatment effect for the change from baseline to end point in 2-hour postprandial values and percent change from baseline for glucose, insulin, and glucagon AUC. Least-squares (LS) means, SEs, 2-tailed 95% CIs, and P values of statistical tests for each treatment group were estimated. Values for AUC were transformed to a logarithmic scale before fitting the model. LS means and 95% CIs were backtransformed to the original scale. The 95% CIs and P values for change from baseline to each scheduled visit in 2-hour postprandial values, and percent change (and ratio) from baseline for AUC, was based on a 1-sample t test. For changes from baseline to end point in HOMA indices, FPG, HbA 1c , and fructosamine, an ANCOVA model with treatment as a factor and baseline value as a covariate was used to test the treatment effect. The LS means, SEs, 2-tailed 95% CIs, and P values for each treatment group were estimated. For all scheduled visits, 95% CIs and P values were calculated from a 1-sample t test.
Demographic characteristics, adverse events, immunogenicity, and laboratory parameters were summarized descriptively. PK parameters were analyzed according to treatment group by using standard noncompartmental methods, and the results are summarized descriptively.
RESULTS
The study was initiated on February 2, 2009, and completed on May 15, 2009; a total of 44 patients were randomized to ITCA 650 treatment and received study drug. Five patients discontinued from participation in the study: 1 patient in the 10-g/d group withdrew consent for participation in the study due to an elevated amylase level and lipase levels, which had resolved before the device was removed. One patient in the 80-g/d group discontinued from the study due to orthostatic hypotension associated with moderate nausea and vomiting. Three patients in the 80-g/d group withdrew consent for participation in the study; all had experienced nausea and vomiting.
At baseline, 59.1% of patients were men; mean (SD) age was 55.7 (6.92) years, mean body mass index was 32.2 (4.33) kg/m 2 , and mean duration of diabetes was 5.9 (4.12) years (Table I) . Mean HbA 1c was 7.6%, and 84% of patients were receiving pharmacologic therapy for diabetes.
Pharmacokinetics
Plasma exenatide levels were below the level of quantitation (29.3 pg/mL) at baseline. Within 12 hours of ITCA 650 placement, 32 of the 44 patients had detectable levels of exenatide. Mean plasma concentrations reached a plateau at ϳ24 hours, and plasma exenatide levels were maintained for the remainder of the R.R. Henry et al.
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28 days of treatment (Figure 1) . Plasma exenatide levels declined rapidly after ITCA 650 was removed, and by 24 hours, had fallen below the level of quantitation in all patients. Mean C max , C ss , C min , and AUC ss for exenatide increased proportionally over the dose range from 10 to 80 g/d (Table II) . Median T max did not vary among the 4 doses of ITCA 650.
PD Effects
Mean FPG decreased significantly (P Ͻ 0.01) from baseline to end point in the 20-, 40-, and 80-g/d groups of ITCA 650 (Table III) . A dose-proportional change from baseline was noted for FPG at each time point (Figure 2) . Similarly, 2-hour PPG decreased significantly (P Ͻ 0.05) from baseline to end point in the 20-, 40-, and 80-g/d groups; mean changes were dose proportional (Figure 3) . Mean HbA 1c levels decreased significantly (P Ͻ 0.001) from baseline to end point in all treatment groups. Mean plasma fructosamine levels decreased significantly (P Ͻ 0.01) from baseline to end point in all dose groups. Plasma glucose AUC decreased significantly (P Յ 0.001) during meal tolerance No consistent changes were observed in mean fasting plasma insulin, C-peptide levels, or 2-hour postprandial insulin. In the 10-g/d group, significant (P Ͻ 0.05) increases in 2-hour postprandial insulin were observed (Table III) . Significant increases were observed from baseline to end point in mean HOMA-␤ in the 40-and 80-g/d groups (P Ͻ 0.05).
Total cholesterol (P ϭ 0.015) and LDL-C (P ϭ 0.046) were significantly lower in the 40-g/d group. No other significant changes from baseline to end point were observed for lipid parameters. Mean weight decreased from baseline to day 29 in all treatment groups. The mean change ranged from Ϫ0.2 kg for 10 g/d to Ϫ3.0 kg for 80 g/d (P Ͻ 0.001) ( Table III) .
Tolerability
Overall, ITCA 650 was very well tolerated. All adverse events were mild or moderate in severity, except for 1 patient in the 80-g/d dose group who experienced severe nausea and vomiting. Adverse events tended to abate after the first week. No patient experienced a serious adverse event during the trial, and no patients died. The most common adverse events related to ITCA 650 were nausea (41%), decreased appetite (36%), vomiting (27%), early satiety (11%), and dizziness (9%) ( Table IV) . A trend toward increased adverse events was observed in the higher dose groups. The proportion of patients who experienced no episodes of nausea or vomiting at weekly intervals approached 100% in all groups, with the exception of the 80-g/d group during weeks 1 and 2 (Figure 4) .
The most common local adverse events related to ITCA 650 were local incision site complication (50%), injection site erythema (48%), incision site hemorrhage (27%), incision site pain (23%), incision site edema (16%), and injection site blister (11%). No dose relationship was observed for these local adverse events. Most of the placement site reactions disappeared after 1 week. No patients were terminated from the study due to placement/removal site reactions.
Two patients experienced an adverse event that led to the removal of ITCA 650. One patient in the 10-g/d group experienced an increase in serum amylase and lipase, which led to removal of the ITCA 650 on day 13. The elevation of amylase and lipase resolved in this patient before removal of ITCA 650. A patient in the 80-g/d group experienced moderate nausea and vomiting and orthostatic hypotension, which resolved after ITCA 650 was removed on day 6. In addition, 3 patients in the 80-g/d group terminated the study prematurely on day 8, day 14, and day 15, respectively, for nausea and vomiting. One patient in the 40-g/d group who was receiving metformin was reported to have asymptomatic hypoglycemia, and 1 patient in the 80-g/d group who was receiving pioglitazone/ metformin combination therapy experienced a single symptomatic episode of hypoglycemia. Both events were considered by the investigator to be mild in intensity, and neither event was considered related to the study drug.
There were no clinically significant treatment-associated trends in vital signs or physical examination 
Antibodies
Serum anti-exenatide antibodies were absent in all patients at baseline but were found in 12 patients on day 29, day 30, and/or day 36 (3, 4, 4, and 1 patient receiving 10, 20, 40, and 80 g/d of ITCA 650, respectively). Of note, none of the 5 patients who terminated early (between days 6 and 15) were antibody positive at termination or at 7 days posttermination. Antibody titers in patients who were confirmed positive for antibodies ranged from Ͻ20 to 18,330; there was no clear relationship to treatment group. The presence of antiexenatide antibodies did not seem to alter the PK profile of ITCA 650. Other parameters related to glycemic control were improved with ITCA 650. Plasma fructosamine, which is an earlier indicator of glycemic control than HbA 1c , 17, 18 was significantly decreased in all dose groups. HOMA-␤, an indicator of pancreatic ␤-cell activity, 19 increased significantly with the 40-and 80-g/d doses of ITCA 650.
Mean plasma concentrations of exenatide rose in a dose-dependent manner, reached a plateau at 24 hours after ITCA 650 placement, and remained relatively steady over the treatment period. Plasma levels declined rapidly after removal of ITCA 650. At 24 hours after removal, exenatide levels had fallen below the level of detection in all patients. This finding is in contrast to data reported for exenatide once weekly, which took 2 weeks to reach therapeutic levels, 6 to 7 weeks to reach steady-state plasma levels, 20 and 6 weeks to decrease below levels considered to have a therapeutic effect after treatment cessation.
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ITCA 650 was generally well tolerated by patients. The most common adverse effects were gastrointestinal (nausea, vomiting, and early satiety). These effects generally occurred within the first week after placement of ITCA 650, abated with time, and were more common in the higher dose groups. By week 4, no patients were experiencing nausea or vomiting, which is in contrast to the experience with exenatide BID and Clinical Therapeutics exenatide once-weekly injection. 12, 21 Four of 11 patients in the 80-g/d dose group discontinued the study prematurely due to nausea and vomiting. This outcome suggests that a lower introductory dose might be necessary to mitigate these symptoms. Local effects at the site of placement/removal were relatively common, consistent with the normal reparative process, and were mostly mild and self-limiting; none of the local reactions necessitated removal of ITCA 650.
This study demonstrated that ITCA 650 provides continuous and consistent SC delivery of exenatide that was generally well tolerated and may allow for the administration of higher doses of exenatide compared with exenatide BID. In contrast to the peaks and troughs in plasma levels noted with exenatide BID injections, constant plasma exenatide concentrations achieved with ITCA 650 may lead to improved glycemic control. Based on the long-term stability of exenatide in the ITCA 650 formulation and the small daily dosage requirements, a single ITCA 650 can store and release exenatide for up to 1 year. In the current study, only 2 patients reported mild episodes of hypoglycemia, 1 of which could be more accurately characterized as asymptomatic low blood glucose.
An important barrier to optimizing glycemic control in patients with type 2 diabetes is poor adherence and persistence rates during chronic long-term treatment. In general, poor adherence to medications is known to result in poor disease control and an increase in hospitalization and health care costs. Major factors contributing to poor adherence to diabetes medications are concerns regarding the risks of therapy and complex dosing regimens. The need for repeated injections of GLP-1 receptor agonists creates a barrier to long-term patient adherence and compliance with therapy. Examination of persistence rates to injectable antidiabetes drugs over 12 months from a pharmacy claims database found a mean persistence of 7.8 months among patients receiving exenatide injection therapy. 22 ITCA 650 may have several advantages compared with exenatide injections and depot formulations of exenatide. The constant delivery of exenatide with ITCA 650 eliminates the peak-to-trough variability in blood concentrations, which may result in a lower incidence of adverse reactions compared with the injectable forms of exenatide. ITCA 650 may be easily removed if necessary to provide an immediate drop in circulating exenatide plasma levels. The potential to ensure 100% adherence with ITCA 650 may improve compliance and adherence and could therefore improve long-term therapeutic outcomes.
22,23

CONCLUSIONS
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SUPPLEMENTAL MATERIAL
A Supplemental Table accompanying this article Description and summary of implantation procedure for ITCA 650 ITCA 650 utilizes a novel drug delivery technology to provide continuous and controlled subcutaneous delivery of exenatide for as long as one year of treatment at a precise and predetermined rate. Initiating treatment with ITCA 650 involves the subcutaneous placement of a matchstick-size osmotic mini-pump done during a short office procedure that can be performed by a physician, physician's assistant or other licensed practitioner. The figure provides an illustration of ITCA 650. ITCA 650 consists of a cylindrical titanium alloy reservoir with external dimensions of 4 mm in diameter by 44 mm in length. The reservoir is capped at one end by a controlled-rate, semi-permeable membrane and capped at the other end by a diffusion moderator through which drug formulation is released from the drug reservoir. The drug formulation, piston and osmotic engine are contained inside the cylinder. 
SUPPLEMENTARY TABLE
Schematic of ITCA 650
ITCA 650 releases drug at a predetermined rate based on the principle of osmosis. Water from the extracellular space enters through the semi-permeable membrane directly into the osmotic engine that expands to drive the piston at a slow and consistent rate of travel. Movement of the piston forces the drug formulation to be released through the orifice of the diffusion moderator.
The sterile ITCA 650 is placed in the horizontal plane subcutaneously into one of the four abdominal quadrants with a placement tool using sterile technique. The intended placement site is marked, cleaned with an antiseptic agent, draped and anesthetized. Once adequate anesthesia is achieved, a small (‫5ف‬mm deep) incision is made. The tip of the cannula of the placement tool that has been loaded with the ITCA 650 is inserted into the incision. The tool is immediately leveled and advanced parallel to the surface of the skin to an indicator band on the placement tool. The cannula of the placement tool is then retracted into its handle, leaving the ITCA 650 in position directly under the skin. The incision is then closed with Steri-Strips TM and covered with a bandage. Removal requires similar skin preparation and adherence to sterile technique as placement. The ITCA 650 is immobilized and a small ‫5ف(‬ mm) incision is made directly over one end of the device. The ITCA 650 is then gently pushed towards the incision and removed with a hemostat.
A new ITCA 650 can be placed in the same incision from which the old device has been removed. The incision is then closed with Steri-Strips TM and covered with a bandage. Patients are instructed to keep the area clean and dry for 24 hours, to allow the Steri-Strips TM to fall off, and to avoid heavy lifting and strenuous physical activity for 48 hours.
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